|Awarded On||February 16, 2022|
|Title||Determining the mechanisms underlying sarcomatoid differentiation in renal cell carcinoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Thomas J Carroll|
|Cancer Sites||Kidney and Renal Pelvis|
Approximately 6,000 Texans will be diagnosed with kidney cancer each year. Tragically, more than 1,300 will succumb to the disease. Sarcomatoid renal cell carcinoma (sRCC) is the most aggressive type of kidney cancer with the worst prognosis. There are currently no effective treatments for this disease. sRCC has always been considered a "terminal stage" of RCC meaning that it represents tumors that have acquired multiple mutations and therefore no longer look anything like a kidney.
We recently found that mutation of only two genes is sufficient to cause metastatic sRCC in mice. When we compared the molecular characteristics of the mouse tumors to hundreds of human RCC tumors, we found that ...